- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 239/48 - Two nitrogen atoms
Patent holdings for IPC class C07D 239/48
Total number of patents in this class: 1125
10-year publication summary
|
93
|
92
|
69
|
79
|
55
|
63
|
46
|
53
|
32
|
24
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Rigel Pharmaceuticals, Inc. | 533 |
36 |
| Bristol-myers Squibb Company | 4848 |
35 |
| Signal Pharmaceuticals, LLC | 181 |
35 |
| Boehringer Ingelheim International GmbH | 4648 |
23 |
| Novartis AG | 10656 |
21 |
| Janssen Sciences Ireland UC | 182 |
20 |
| Merck Patent GmbH | 5756 |
16 |
| Korea Research Institute of Chemical Technology | 1406 |
15 |
| Alexion Pharmaceuticals, Inc. | 640 |
14 |
| Afferent Pharmaceuticals, Inc. | 25 |
13 |
| Dana-Farber Cancer Institute, Inc. | 2615 |
13 |
| H. Lee Moffitt Cancer Center and Research Institute, Inc. | 981 |
13 |
| Celgene Avilomics Research, Inc. | 31 |
12 |
| Corteva Agriscience LLC | 2702 |
12 |
| FUJIFILM Corporation | 29752 |
11 |
| Takeda Pharmaceutical Company Limited | 2717 |
11 |
| Portola Pharmaceuticals, Inc. | 87 |
11 |
| Genentech, Inc. | 4008 |
10 |
| AstraZeneca AB | 2857 |
10 |
| Roche Palo Alto LLC | 70 |
10 |
| Other owners | 784 |